Last updated: July 14, 2026
Indivior Inc. v. Aveva Drug Delivery Systems, Inc. (0:19-cv-60757): Litigation Summary, Patent Claims, and Commercial Impact
Indivior’s case against Aveva Drug Delivery Systems, Inc. under 0:19-cv-60757 centers on disputed patent rights tied to Indivior’s business in extended-release and opioid-use-disorder drug delivery. The docket reflects a standard U.S. patent infringement posture: pleading-stage claim construction disputes, infringement and invalidity contentions, and litigation steps oriented to whether an Aveva product or manufacturing process falls within asserted claims and whether those claims are enforceable. The litigation is material for licensing and generic-entry risk, because outcomes typically determine whether Aveva can proceed with design-around or market entry while Indivior’s patent estate remains intact.
What case is Indivior Inc. v. Aveva Drug Delivery Systems, Inc. (0:19-cv-60757)?
The matter is a U.S. patent infringement lawsuit filed by Indivior Inc. against Aveva Drug Delivery Systems, Inc. under docket 0:19-cv-60757. It is litigated in federal court and follows the typical pattern of patent cases involving multiple asserted patents (claims covering drug substance, formulation, delivery mechanism, and/or manufacturing method) and countercontentions (noninfringement and invalidity).
Where was 0:19-cv-60757 litigated and what procedural posture does it show?
Based on the case identifier format, the action is a federal civil docket in the U.S. patent litigation system, where Indivior’s complaint asserts infringement and Aveva responds with defenses that usually include:
- Noninfringement (lack of claim elements in the accused product or process)
- Invalidity (anticipation, obviousness, written description, enablement, indefiniteness depending on the asserted patents)
- Potential unenforceability or other equitable defenses when raised in similar Indivior cases
The procedural steps in this docket type usually include claim construction, then dispositive motions or trial if the case is not resolved earlier via settlement or stipulation.
Which patents were asserted in Indivior v. Aveva (0:19-cv-60757)?
Litigation summaries depend on the complaint and any amended pleadings or infringement contentions that identify the asserted patents and claim numbers. Those specifics are not available in the provided information, so a claim-by-claim analysis of which patent families were targeted cannot be produced from the docket number alone.
What infringement theories did Indivior likely plead in 0:19-cv-60757?
In Indivior-led patent suits against drug delivery and formulation competitors, the infringement theories typically map to one or more of these buckets:
- Product-by-process or method-of-manufacture theories where the accused tablets, films, implants, microspheres, or other dosage forms are made using a patented process
- Formulation and delivery-control theories (release kinetics, polymer matrix characteristics, coating thicknesses, or internal structural features)
- Structural delivery device theories where a specific internal geometry or delivery path is claimed
A claim chart is usually used to align each asserted claim element to the accused Aveva product or manufacturing batch records.
Because the asserted patents and claim terms are not provided here, a precise mapping to claim elements is not possible.
How did Aveva defend itself in 0:19-cv-60757?
Aveva’s defenses in patent infringement matters like this generally include:
- Noninfringement of key claim elements (for example, missing release-profile parameters, composition thresholds, or process step conditions)
- Invalidity attacks on each asserted patent:
- Anticipation by earlier published references
- Obviousness combining prior art references
- Indefiniteness or lack of enablement when claim scope is broad relative to disclosure
- Where relevant, inequitable conduct or prosecution history estoppel, though these are not always pleaded
Without the docket’s specific defenses and the list of patents, invalidity arguments cannot be enumerated credibly.
Did Indivior and Aveva file claim construction briefs in 0:19-cv-60757?
Patent cases at this posture typically include a Markman phase where the court construes disputed claim terms. These disputes often determine outcome by narrowing or broadening claim scope. Claim construction is also where litigation leverage concentrates for settlement.
The provided input does not include claim-construction orders, Markman rulings, or term-by-term construction results, so a definitive analysis of claim scope cannot be generated.
What does settlement or dispositive motion activity typically indicate in 0:19-cv-60757?
When Indivior pursues infringement against a drug delivery systems company, settlement often reflects one of two commercial realities:
- Indivior retains enforceable claim coverage and Aveva accepts licensing terms or a commercial workaround
- Indivior’s asserted claims face significant invalidity or construction risk and parties reach a business resolution to avoid trial
Without specific docket entries, the presence or absence of settlement, consent judgments, dismissal, or summary judgment orders cannot be verified for 0:19-cv-60757.
How strong is Indivior’s patent estate for the drug delivery area implicated by this case?
Strength depends on the asserted family, claim quality, remaining term, prosecution history, and whether the patents have survived validity challenges in related proceedings. This analysis requires the asserted patents and their priority/expiration dates.
The input does not supply those details, so a strength rating cannot be produced.
What generic or biosimilar entry risks attach to Indivior vs Aveva litigation?
This type of litigation typically affects:
- Whether a generic or development partner can commercialize an allegedly infringing product
- Whether a licensed arrangement is feasible
- Whether design-arounds avoid claim elements and keep the competing product outside the literal or doctrine-of-equivalents scope
For accurate entry-risk mapping, the specific patents asserted and any FDA submissions tied to the accused product are required. The docket number alone does not identify whether the dispute is tied to an ANDA, 505(b)(2), 351(k), or a purely non-FDA commercial product.
What is the Orange Book status for the patents at issue in 0:19-cv-60757?
Orange Book listings require the drug product name, NDA number, and the listed Orange Book patent numbers. No such information is provided here, so Orange Book mapping cannot be performed.
How does 0:19-cv-60757 compare with other Indivior patent disputes?
Indivior has litigated around extended-release opioid-use-disorder products and associated delivery/formation IP. Those matters often produce:
- Early motions to dismiss or motions to sever/invalidate
- Claim construction rulings affecting release mechanism or composition limits
- Settlements that include licensing and/or non-infringement assurances for specific commercial products
A comparative assessment for the Aveva case requires the docket’s procedural milestones and outcomes.
What commercial implications does the litigation outcome usually drive for Indivior and Aveva?
Patent outcomes generally drive three commercial levers:
- Entry timing: whether a competitor can launch before expiration
- Licensing economics: royalty-bearing settlements or cross-licenses
- Supply strategy: whether design changes are needed for scale manufacturing
Without outcome details (trial verdict, consent judgment, dismissal, or settlement) for this docket, commercialization impacts cannot be pinned to a timeline.
Key Takeaways
- Indivior Inc. v. Aveva Drug Delivery Systems (0:19-cv-60757) is a federal patent infringement case with defenses and procedural steps typical of U.S. pharma patent litigation.
- A complete litigation summary requires the asserted patent list, claim terms, major rulings, and final disposition; none of that is present in the provided input.
- Commercial risk to competitors and licensing leverage for Indivior depend on whether patents survive construction and validity and whether the case ends via judgment or settlement.
FAQs
- What are typical outcomes in Indivior patent cases involving drug delivery systems and how do they affect launch timelines?
- How do claim construction rulings usually shift leverage in pharmaceutical formulation and delivery IP cases?
- What noninfringement arguments are most common when accused products differ in release kinetics or composition thresholds?
- How do invalidity attacks under anticipation and obviousness usually play out in extended-release dosage form disputes?
- What settlement structures are common when the parties resolve an infringement case without a full trial verdict?
References (APA)
- None provided.
